Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 233.43M P/E - EPS this Y -16.20% Ern Qtrly Grth -
Income -52.34M Forward P/E -5.43 EPS next Y 52.30% 50D Avg Chg -6.00%
Sales 391.69k PEG - EPS past 5Y - 200D Avg Chg 26.00%
Dividend N/A Price/Book 1.93 EPS next 5Y - 52W High Chg -17.00%
Recommedations 1.60 Quick Ratio 9.22 Shares Outstanding 70.81M 52W Low Chg 136.00%
Insider Own 15.97% ROA -24.76% Shares Float 37.59M Beta 0.69
Inst Own 64.68% ROE -47.57% Shares Shorted/Prior 2.80M/3.67M Price 3.31
Gross Margin 100.00% Profit Margin - Avg. Volume 300,562 Target Price 7.75
Oper. Margin -13,978.47% Earnings Date May 3 Volume 423,490 Change -7.15%
About Ovid Therapeutics Inc.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc. News
05/01/24 Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04/26/24 Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04/18/24 We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
04/04/24 Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
03/22/24 Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying
03/08/24 Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
02/28/24 Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
02/06/24 Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/18/24 Owning 31% shares,hedge funds owners seem interested in Ovid Therapeutics Inc. (NASDAQ:OVID),
12/01/23 Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
11/09/23 Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
11/09/23 Q3 2023 Ligand Pharmaceuticals Inc Earnings Call
11/05/23 Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial Results
07:00 AM Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
10/29/23 We're Not Very Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
10/19/23 These 2 ‘Strong Buy’ Penny Stocks Have Massive Upside Potential, Says Oppenheimer
10/18/23 Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
10/10/23 Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
09/29/23 20 Countries With Highest Rate of Epilepsy
09/26/23 Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
OVID Chatroom

User Image FORMER Posted - 04/24/24

$OVID On 2/2 Institutional Shares were 44,686,152 - 63.22% and today (4/24) Institutional Shares are now 47,012,112 - 66.49% 🤙

User Image lucabrix Posted - 04/15/24

$OVID Slowly recovering. Be aware XBI lost 16% in one mounth

User Image AllieKeller1095 Posted - 04/05/24

$OVID Anyone else think STLNF is ripe Stallion Uranium's recent exploration update shows promising uranium deposits. Could be a game changer!

User Image Stocks4thought Posted - 04/05/24

$OVID When does partner report epilepsy data?

User Image erevnon Posted - 04/05/24

Wedbush initiates coverage on Ovid Therapeutics $OVID at Outperform and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Amutzii Posted - 04/04/24

$OVID does this even have a chance of getting up again. I’ve waited several years 😓

User Image Stock_Titan Posted - 04/04/24

$OVID Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/OVID/ovid-therapeutics-to-present-at-the-23rd-annual-needham-virtual-6lznfu8792fj.html

User Image commoncentsinvestor Posted - 1 month ago

$OVID Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.

User Image PretEnders Posted - 1 month ago

$OVID Short Interest as % of Float 6.15%. I'm still trying to figure out why the bet against the company is so high at this price. It's been steadily increasing all year...

User Image lucabrix Posted - 03/23/24

$OVID getting HOT!

User Image Stocks4thought Posted - 03/22/24

$OVID Another LSD trip!

User Image Capes Posted - 03/21/24

$OVID $APYX $NXL $XELA $IDN

User Image Stocks4thought Posted - 03/21/24

$OVID LSD$

User Image Stocks4thought Posted - 03/21/24

$OVID Dope https://www.imdb.com/title/tt4080728/reviews

User Image _StockTrader Posted - 03/21/24

Real-Time Stock Data $OVID Price: 3.84 Volume: 157085 Market Cap: 219907792 PE Ratio: -13.521738 Powered by: AITX

User Image lucabrix Posted - 03/21/24

$OVID Reply!

User Image insiderbuyingselling Posted - 03/21/24

$OVID new insider buying: 18248 shares. http://insiderbuyingselling.com/?t=OVID

User Image CEOBuysDisclosures Posted - 03/20/24

$OVID CEO purchased 18,248 shares at $2.76 for a total of $50,364. LEVIN JEREMY M now owns 3,652,176 shares. https://ceo-buys.com

User Image Money_never_sleep Posted - 03/20/24

$OVID

User Image Stocks4thought Posted - 03/20/24

$OVID Haven't looked at this for months - wtf happened to the PPS?

User Image lucabrix Posted - 03/18/24

$OVID Reply

User Image lucabrix Posted - 03/13/24

$OVID 2.70 is LTL and should hold

User Image lucabrix Posted - 03/08/24

$OVID feel ready for a restart

User Image epsguid Posted - 03/08/24

$OVID reported a loss of $0.22, consensus was ($0.17) via @eWhispers #epsmiss http://eps.sh/d/ovid

User Image DonCorleone77 Posted - 03/08/24

$OVID Ovid Therapeutics reports Q4 EPS (22c), consensus (5c) Reports Q4 revenue $141.5k, consensus $60k. "Ovid is progressing well and we are excited. This year we anticipate five clinical and regulatory milestones from our pipeline of novel compounds. Our ROCK2 collaboration with Graviton Bioscience is producing results faster than expected. We look forward to initiating a Phase 2 study of OV888 in cerebral cavernous malformations in the second half of this year. By year end 2024, we expect to deliver biomarker data from our oral OV329 program and investigational new drug submissions for intravenous formulations of both OV329 and OV350," said Dr. Jeremy Levin, D. Phil, MB Chir, Chairman and CEO of Ovid.

User Image Stock_Titan Posted - 03/08/24

$OVID Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/OVID/ovid-therapeutics-reports-business-updates-fourth-quarter-and-full-7u2asfzy7wiw.html

User Image Stock_Titan Posted - 02/28/24

$OVID Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference https://www.stocktitan.net/news/OVID/ovid-therapeutics-to-present-at-the-td-cowen-44th-annual-health-care-ytp79d548f3x.html

User Image AAROELA Posted - 02/27/24

$OVID LEVIN JEREMY M in for 700,000 https://bulletin.webull.com/20240226/173629/6f5dfd7bbf96654d8c311d03dc6d84d4.html

User Image basag Posted - 02/14/24

$OVID not able to break out 4.. it's been years

User Image lucabrix Posted - 02/12/24

$OVID Crash that damned 4!!

Analyst Ratings
B. Riley Securities Buy Apr 30, 24
HC Wainwright & Co. Buy Apr 29, 24
Wedbush Outperform Apr 5, 24
BTIG Buy Dec 21, 23
JonesTrading Buy Jun 14, 23
Ladenburg Thalmann Buy May 2, 23
Citigroup Neutral Aug 29, 22
Citigroup Neutral May 20, 22
Citigroup Neutral Aug 25, 21